Arimoclomol
Brand names: Miplyffa · Active ingredient: Arimoclomol Citrate
In short: MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.
What is Arimoclomol used for?
MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.
Arimoclomol dosage
The recommended oral dosage of MIPLYFFA, in combination with miglustat, for patients with an actual body weight of:
8 kg to 15 kg, is 47 mg three times a day
> 15 kg to 30 kg, is 62 mg three times a day
> 30 kg to 55 kg, is 93 mg three times a day
> 55 kg, is 124 mg three times a day
Administer MIPLYFFA with or without food.
Missed Dose
If a dose of MIPLYFFA is missed, advise the patient to skip the missed dose and to resume taking the prescribed dose at the next scheduled time.
The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR ≥ 50 mL/minute is the same as the recommended dosage in patients with normal renal function .
For patients with an eGFR ≥ 15 to < 50 mL/minute, the recommended oral dosage of MIPLYFFA, in combination with miglustat, for patients with an actual body weight of :
8 kg to 15 kg, is 47 mg two times a day
> 15 kg to 30 kg, is 62 mg two times a day
> 30 kg to 55 kg, is 93 mg two times a day
> 55 kg, is 124 mg two times a day
Administer MIPLYFFA with or without food.
Swallow MIPLYFFA whole. However, for patients who have difficulty swallowing capsules, administer MIPLYFFA in one of two ways:
Oral Administration
Carefully open the capsule and sprinkle the entire contents into 15 mL of water or apple juice or 15 mL of soft food (e.g., applesauce, pudding, or yogurt).
Stir the mixture for 15 seconds.
Consume the entire mixture immediately.
Feeding Tube Administration (nasogastric or gastric tube)
Carefully open the capsule and sprinkle the entire contents into 20 mL of water. Do not add the capsule contents to other liquids besides water.
Stir the mixture for 15 seconds.
Administer the entire mixture immediately via feeding tube.
Flush the feeding tube with 5 mL of water after administration.
Do not save the mixture for later use.
How to take Arimoclomol — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Instructions for Use).
Drug Interactions
Advise the patient to inform his/her healthcare provider if he/she is taking, or plan to take, any prescription or over-the-counter medications and supplements because of the potential for drug interactions .
Hypersensitivity Reactions
Advise the patient or caregiver to contact his/her healthcare provider immediately if urticaria (hives), shortness of breath, persistent cough, or facial swelling develop in response to MIPLYFFA treatment .
Embryofetal Toxicity
MYPLIFFA may cause embryo-fetal harm. Advise the pregnant female of the potential risk to the fetus. Advise a female of reproductive potential and caregiver to inform their healthcare provider of a known or suspected pregnancy . Counsel females of reproductive potential about pregnancy planning and prevention .
Infertility
Advise the female and male of reproductive potential that MIPLYFFA may impair fertility .
Manufactured by: Zevra Denmark A/S 2000 Frederiksberg, Denmark
Manufactured for: Zevra Therapeutics, Inc. Boston, MA 02110, USA © 2024, 2025 Zevra Therapeutics, Inc. All rights reserved. U.S. …
Warnings & precautions
Do not take this medicine if: None.
Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1 : two patients reported both urticaria and angioedema (6%) and one patient (3%) experienced urticaria alone. The reactions occurred within the first two months of treatment. Discontinue MIPLYFFA in patients who develop severe hypersensitivity reactions. If a mild or moderate hypersensitivity reaction occurs, stop MIPLYFFA and treat promptly. Monitor the patient until signs and symptoms resolve .
Based on findings from animal reproduction studies, MIPLYFFA may cause embryofetal harm when administered during pregnancy. In animal reproduction studies, oral administration of arimoclomol to pregnant rats and rabbits resulted in post-implantation loss and structural abnormalities in offspring. These occurred at exposures equal to or greater than 10- and 5-fold, for rats and rabbits respectively, the human exposure at the maximum recommended human daily dose of 372 mg. Advise pregnant females of the potential risk to the fetus. Consider pregnancy planning and prevention for females of reproductive potential .
Across clinical trials of MIPLYFFA consisting of patients with NPC, healthy subjects, and patients with other diseases, there were mean increases in serum creatinine of 10% to 20% compared to baseline. These increases occurred mostly in the first month of MIPLYFFA treatment and were not associated with changes in glomerular function. The increases in serum creatinine may be due to inhibition of renal tubular secretion transporters .
During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function such as BUN, cystatin C, or measured GFR. Increases in creatinine reversed upon MIPLYFFA discontinuation .
Arimoclomol side effects
The following clinically significant adverse reactions are described below and elsewhere in the labeling:
Hypersensitivity Reactions .
Increased Creatinine without Affecting Glomerular Function .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of MIPLYFFA was evaluated in a randomized, double-blind, placebo-controlled, 12-month trial (Trial 1), which included 50 patients 2 to 19 years old with NPC . Patients received weight-adjusted doses of MIPLYFFA (31 to 124 mg orally three times daily); 28 of the patients were exposed to MIPLYFFA for one year. In Trial 1, 78% of patients received miglustat. Forty-one out of 50 patients that were enrolled in Trial 1 continued into an open-label extension trial, which included 39 patients treated with MIPLYFFA for more than 1 year, 34 patients treated with MIPLYFFA for more than 2 years, and 17 patients treated with MIPLYFFA for more than 5 years.
The most common adverse reactions in Trial 1 (≥ 15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight. …
Drug interactions
Arimoclomol is an inhibitor of the organic cationic transporter 2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates . When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.
About this medicine
MIPLYFFA capsules contain arimoclomol citrate. Arimoclomol citrate is a crystalline powder of white to off-white color that is freely soluble in water. The chemical name is N-[(2R,Z)-2-hydroxy-3-(1piperidyl)propoxy]pyridine-3-carboximidoyl chloride, 1-oxide, citrate.
The empirical formula is C20H28ClN3O10 and the molecular weight is 505.90 g/mol. The chemical structure is:
MYPLIFFA contains 47 mg, 62 mg, 93 mg, or 124 mg of arimoclomol (equivalent to 75 mg, 100 mg, 150 mg, or 200 mg of arimoclomol citrate). The inactive ingredients are microcrystalline cellulose (MCC) and magnesium stearate. The inactive ingredients are not water soluble and will remain undissolved if the contents of the capsule are added to beverages or soft food .
The capsule shells contain hypromellose, titanium dioxide, and one or more of the following: Brilliant Blue FCF-FD&C Blue 1, Yellow iron oxide and Red iron oxide.
How it works: The mechanism(s) by which arimoclomol exerts its clinical effects in patients with NPC is unknown. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5feffc0e-453d-47fa-91dd-38d4952309bc. Read the full official label on DailyMed.